QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations
PR Newswire•07/10/2026•07:13 ET
2
Key Highlights
- ➤QuidelOrtho appointed Sanjeev Sharma vice president of investor relations, effective September 28, 2026
- ➤Sharma brings more than 20 years of investor relations, strategy and equity research experience
- ➤Sharma previously served as Teva Pharmaceuticals’ senior director of investor relations
- ➤CFO Micah Young said Sharma will sharpen communications and deepen shareholder engagement
Expert Statements
Micah Young, Chief Financial Officer of QuidelOrtho
“We are pleased to welcome Sanjeev to QuidelOrtho. He brings a valuable combination of investor relations leadership, healthcare experience, financial expertise and capital markets perspective. Sanjeev's experience partnering with executive teams and translating strategy and performance into a clear investor narrative will be especially valuable as we sharpen our communications and deepen our engagement with shareholders and analysts.”
Sanjeev Sharma, Vice President, Investor Relations of QuidelOrtho
“I am excited to join QuidelOrtho at this important stage in the company's journey. QuidelOrtho plays a vital role in advancing healthcare around the world. I look forward to partnering with the leadership team to deepen engagement with the investment community and communicate the company's strategic priorities and progress focused on long-term value creation.”
QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations PR Newswire
SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions, has appointed Sanjeev Sharma, CFA, as Vice President, Investor Relations, effective September 28, 2026.
Get started
Create a free account to read the full story.